Skip to main content
OpenTrials
Completed

NCT Number: NCT03925480

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

A trial to assess cumulative incidence of skin and soft tissue infections (SSTI) in infants (by three months of age) born to mothers receiving a single-dose of 2 grams of oral azithromycin during labour (or immediately prior to delivery in the case of caesarean section), compared to infants whose mothers received placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Infections Bacterial Infections and Mycoses Infections

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Colonial War Memorial Hospital and Mother and Child Health Clinics

Suva, Central, Fiji

About this study

PreYIAL is a Phase III, double-blind, randomised, placebo controlled two arm trial of a single 2g dose of azithromycin or placebo, administered to women who have been admitted for delivery of their baby (either following onset of labour or for caesarean section).

The trial includes an estimated 2110 mothers/infant pairs (1055 per arm), with 12 months of follow-up for the mother/infant pair.

A swab-study within the main study involves 940 of the mother/infant pairs enrolled and involves follow-up for bacterial carriage outcomes, for 12 months.These swab-study participants will also be included in assessments of the infant and maternal microbiome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women at least 18 years old intending to deliver at Colonial War Memorial Hospital (CWMH)
  • Women who have been admitted to CWMH for delivery at the time of eligibility assessment
  • Women who expect to be available, with their infant, for the duration of the study, and who agree to adhere to all protocol requirements
  • Women who will have a main place of residence within the Greater Suva area for the follow-up period and within a practical distance of the study site to allow compliance with protocol-required visits and follow-up, including attending follow-up at specified clinics
  • Women who have provided written informed consent prior to study-related procedures being performed

Exclusion criteria

  • Women who have a known macrolide allergy
  • Women who have taken antibiotics in the week prior to randomisation
  • A women who is unable or unwilling to provide informed consent for her participation in the trial or the participation of her infant
  • Women who decide prior to randomisation that they are no longer willing to participate or to have their infant participate
  • Women who have ever received, or who are anticipated to receive during the study period, any investigational agent other than the study drug
  • Women who are CWMH, Murdoch Children's Research Institute (MCRI) or study site employees who work directly with study staff, or who are working on the study
  • Women taking warfarin due to the potential for drug interactions with azithromycin
  • Women with any cardiac abnormality
  • Women taking other medications known to prolong the QT interval such as antiarrhythmics; antipsychotic agents; antidepressants; and fluoroquinolones;
  • Women with known electrolyte disturbances: including in cases of hypokalaemia and hypomagnesaemia
  • Women who will undergo general anaesthetic for delivery
  • Women carrying a foetus with intrauterine death confirmed before randomisation
  • Women carrying a foetus with a prognosis unlikely to survive
  • Women with known HIV infection and/or taking nelfinavir
  • Women who have participated in the study during a previous pregnancy
  • Women who have been admitted for management of premature labour who have unruptured membranes (This is a temporary exclusion such that the participant may be assessed for eligibility again in the same or a subsequent admission to CWMH).
  • Women with renal impairment
  • Women with hepatic impairment
  • Women with myasthenia gravis
  • Women who are taking any ergot medications

Treatment and study plan

Azithromycin 500 mg Oral Tablet x 4

Drug

A single prophylactic dose of antibiotic given during labour

Matching Placebo

Drug

Matching Placebo

Primary outcomes

  1. Cumulative incidence of skin and soft tissue infection by 3 months of age in infants

    Time frame: 3 months

    Born to mothers receiving a single dose of 2g Azithromycin during labour. Assessed by history and physical examination at 7 days, 6 weeks and 3 months.

Secondary outcomes

  1. Cumulative incidence of skin and soft tissue infection, and other infections by 12 months of age in infants

    Time frame: Birth to 12 Months

    To compare intervention and placebo groups with regard to the cumulative incidence of infant infection (meningitis, sepsis, pneumonia, SSTI, fever, diarrhoea, urinary tract infection) up to 12 months of age;

  2. Cumulative incidence of maternal infection by 6 weeks and 12 months post-delivery

    Time frame: Delivery to 12 months

    To compare intervention and placebo groups with regard to the cumulative incidence of maternal infection (mastitis, sepsis, post-operative wound infections, SSTI, fever, meningitis, pneumonia, abdominal or pelvic abscess, endometritis, urinary tract infection, pyelonephritis) by six weeks post-delivery, and similarly up to 12 months post-delivery

  3. Cumulative incidence of antibiotic usage by 12 months in infants

    Time frame: Birth to 12 months

    To compare intervention and placebo groups with regard to the cumulative incidence of the number of courses of antibiotics prescribed to the infant up to 12 months of age;

  4. Cumulative incidence of maternal antibiotic usage by 12 months post-delivery

    Time frame: Delivery to 12 months

    To compare intervention and placebo groups with regard to the cumulative incidence of the number of courses of antibiotics prescribed to the mother up to 12 months post-delivery

  5. Number of infant participants with adverse events as assessed by adapted version of CTCAE v5.0 and DAID v2.1

    Time frame: Birth to 12 months

    To compare the number of adverse events including solicited non serious adverse events and all serious adverse events as per study specific definitions throughout the duration of the study.

  6. Number of maternal participants with adverse events as assessed by adapted version of CTCAE v5.0 and DAID v2.1

    Time frame: Delivery to 12 months

    To compare the number of adverse events including solicited non serious adverse events and all serious adverse events as per study specific definitions throughout the duration of the study.

  7. Number of infant and maternal participants with Staphylococcus aureus and/or Group A streptococcus as assessed by real-time quantitative PCR (qPCR) from impetigo swabs

    Time frame: Delivery/birth to 12 months

    The proportion of participants that have Staphylococcus aureus and/or Group A streptoccoccus detected by qPCR from impetigo swabs at key time points throughout the duration of the study, between the two groups

  8. Number of infant and maternal participants with Staphylococcus aureus and/or Group A streptococcus with azithromycin nonsusceptibility cultured from impetigo swabs.

    Time frame: Delivery/birth to 12 months

    The proportion of participants that have Staphylococcus aureus and/or Group A streptococcus that is non susceptible to azithromycin cultured from impetigo swabs at key time points throughout the duration of the study, between the two groups

  9. Swab study outcome - Prevalence of bacterial carriage as assessed by real-time quantitative PCR (qPCR)

    Time frame: Delivery/birth to 12 months

    Bacterial carriage, the proportion of participants that have at least one of the following bacterial species including GBS, SA, SPN, GAS or E. coli, assessed by qPCR at key time points throughout the duration of the study, between the two groups

  10. Swab study outcome - Density of bacterial carriage as assessed by real-time quantitative PCR (qPCR)

    Time frame: Delivery/birth to 12 months

    Density of bacterial carriage, reported as log 10 genome equivalents/ml, of the participants that have at least one of the following bacterial species including GBS, SA, SPN, GAS or E. coli, assessed by qPCR at key time points throughout the duration of the study, between the two groups

  11. Swab study outcome - Risk of maternal carriage identified through qPCR of common organisms relevant to Sexually Transmitted Infections (STI)

    Time frame: Delivery/birth to 6 months

    Maternal carriage of common organisms relevant to Sexually Transmitted Infections (STI) (including Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, HSV-1 and HSV-2) as detected by qPCR at key time points throughout the duration of the study, between the two groups.

  12. Swab study outcome - Risk of antibiotic nonsusceptibility in culture isolates

    Time frame: Delivery/birth to 12 months

    Antibiotic non susceptibility, based on the proportion of samples from mothers and infants that are non susceptible to antibiotics cultured in the two arms, at key time points throughout the duration of the study

  13. Swab study outcome - The prevalence of infants with diagnoses that have been associated with microbiome dysbiosis

    Time frame: Delivery/birth to 6 months

    To compare the infant and maternal microbiome of specified body sites at key time points in the intervention and placebo groups

Sponsors and collaborators

Lead sponsor

Murdoch Childrens Research Institute

Other

Collaborators

  • Ministry of Health, Fiji

Registry information

Official study title

Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL): a Blinded, Randomised, Placebo-controlled Trial

Acronym: PreYIAL

Important dates

Study start
2019
Primary completion
2022
Study completion
2023
First posted
Apr 24, 2019
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.